These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 694712)

  • 1. Circulating antibodies in diabetics treated with conventional and purified insulins.
    Klaff LJ; Vinik AI; Berelowitz M; Jackson WP
    S Afr Med J; 1978 Jul; 54(4):149-53. PubMed ID: 694712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibodies to insulin, pancreatic polypeptide, glucagon, and somatostatin in insulin-treated diabetics.
    Fitz-Patrick D; Patel YC
    J Clin Endocrinol Metab; 1981 May; 52(5):948-52. PubMed ID: 6112233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical aspects of monocomponent insulins in the treatment of diabetes.
    Vinik AI; Joffe BI; Seftel HC; Distiller LA; Jackson WP
    S Afr Med J; 1976 Apr; 50(15):587-91. PubMed ID: 1265555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoimmunity in diabetics induced by hormonal contaminants of insulin.
    Bloom SR; Adrian TE; Barnes AJ; Polak JM
    Lancet; 1979 Jan; 1(8106):14-7. PubMed ID: 83463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decrease of antibodies to insulin, proinsulin and contaminating hormones after changing treatment from conventional beef to purified pork insulin.
    Kurtz AB; Matthews JA; Mustaffa BE; Daggett PR; Nabarro JD
    Diabetologia; 1980; 18(2):147-50. PubMed ID: 6988274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin, pancreatic polypeptide, and glucagon antibodies in insulin-dependent diabetes mellitus.
    Asplin CM; Hollander P; Pecoraro RE; Brodsky J; Palmer JP
    Diabetes Care; 1981; 4(3):337-42. PubMed ID: 7047110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The production and characteristics of anti-insulin, anti-A-component and anti-proinsulin antibodies in patients treated with monocomponent or conventional insulin.
    Kawazu S; Kanazawa Y; Miki E; Hayashi M; Sando H; Kajinuma H; Iwamoto Y; Akanuma Y; Kosaka K
    Acta Diabetol Lat; 1979; 16(4):339-51. PubMed ID: 399151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of circulating insulin and proinsulin-binding antibodies in autoimmune hypoglycemia.
    Goldman J; Baldwin D; Rubenstein AH; Klink DD; Blackard WG; Fisher LK; Roe TF; Schnure JJ
    J Clin Invest; 1979 May; 63(5):1050-9. PubMed ID: 447827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin antibodies in diabetics receiving a single type of insulin.
    Mincu I; Cheţa D
    Med Interne; 1982; 20(1):9-13. PubMed ID: 6765628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibodies to pancreatic hormones in diabetics treated before 1964 and after 1974.
    Meryn S; Spigland I; Bauman WA
    Clin Immunol Immunopathol; 1986 Aug; 40(2):291-7. PubMed ID: 2872983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin allergy: reaginic antibodies to insulin and proinsulin.
    Kumar D; Rosenquist RJ; Parameswaran V
    J Clin Endocrinol Metab; 1979 Aug; 49(2):252-4. PubMed ID: 457844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antigenicity of "monocomponent" pork insulin in diabetic subjects.
    Yue DK; Turtle JR
    Diabetes; 1975 Jul; 24(7):625-32. PubMed ID: 1171804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controlled study comparing treatment with monocomponent insulin and conventional insulin in patients with lipoatrophy.
    Czyzyk A; Rogala H; Lawecki J
    Acta Diabetol Lat; 1989; 26(1):17-26. PubMed ID: 2665407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Behaviour of insulin antibodies in diabetics treated with different insulins.
    Mincu I; Cheţa D; Ionescu-Tîrgovişte C; Mirodon Z; Sîntu E
    Med Interne; 1980; 18(4):347-52. PubMed ID: 7006044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Proinsulin and a-component antibodies in diabetics treated with monocomponent and conventional insulin].
    Gamba S; Barbero PL; Bollati C; Castellazzi R; D'Adda A; Bruni B
    Minerva Dietol Gastroenterol; 1979; 25(3):309-14. PubMed ID: 400003
    [No Abstract]   [Full Text] [Related]  

  • 16. The immunogenic properties of highly purified insulin preparations: The clinical importance of insulin-binding antibodies.
    Anderson OO
    Acta Endocrinol (Copenh); 1975 Apr; 78(4):723-35. PubMed ID: 1173962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of human insulin (Novo) or pork monocomponent insulin in HLA-DR-typed insulin-dependent diabetic individuals.
    Schernthaner G; Borkenstein M; Fink M; Mayr WR; Menzel J; Schober E
    Diabetes Care; 1983; 6 Suppl 1():43-8. PubMed ID: 6343038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The preparation of highly purified insulin and its clinical use. Insulin Cooperative Study Group].
    Yang J; Fang F; Zhu X; Deng S; Zhou W; Xing Z
    Hua Xi Yi Ke Da Xue Xue Bao; 1991 Jun; 22(2):178-80. PubMed ID: 1786955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical experiences with monocomponent insulins].
    Bruni Bocher K; Giolitti A; Turco GL; Benedetto P; Bruni B
    Minerva Med; 1975 Mar; 66(19):909-30. PubMed ID: 1124144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Glucagon antibodies in the blood of insulin-treated diabetics (effect of monospecific and monocomponent insulin therapy on antibody level)].
    Korányi L; Tamás G; Gerö L; Halmos T; Baranyai E; Büki B
    Orv Hetil; 1981 Jun; 122(23):1371-4. PubMed ID: 7024892
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.